Intellia Therapeutics Inc.

Intellia Therapeutics, a clinical‑stage CRISPR gene‑editing firm, advances in‑vivo NTLA‑2001 (transthyretin amyloidosis) and NTLA‑2002 (hereditary angioedema) and develops allogeneic CAR‑T & NK‑cell therapies, partnering with AvenCell, Kyverna, ONK & ReCode.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 403
HQ: Cambridge

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
NTLA	Intellia Therapeutics Inc. Cap: 1.2B	EQUITY	NMS	USD	US45826J1051	Active	📈